|
Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.
|
| | | Contact Information | |
Address: |
1167 Kensington Crescent NW, Ste. 210
Calgary, Alberta T2N 1X7, Canada
| | Phone: | 403-670-7377 | | Fax: | 403-283-0858 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.00 M | | Employees (2008): | 16 | | Employee Growth (1 yr): | 14.30% |
|
|
Key People
| | • |
Chairman, President, and CEO:
Bradley G. (Brad) Thompson
| | • |
COO:
Matthew C. (Matt) Coffey
| | • |
CFO and Director:
Douglas A. (Doug) Ball
|
|
|
